SCREENING FOR TOLEROGENIC ADJUVANTS TO ENHANCE ANTIGEN SPECIFIC IMMUNOTHERAPY FOR CELIAC DISEASE.

筛选耐受性佐剂以增强乳糜泻的抗原特异性免疫治疗。

• 批准号: 10933263
• 负责人: CHRISTINA CARGILL
• 金额: $ 59.99万
• 依托单位: QRONO, INC
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-30 至 2025-09-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10933263
• 关键词: Adjuvant; Antigens; Autoimmune Diseases; Barley; Biological Assay; Celiac Disease; Cells; Chronic; Clinical; Contractor; Dendritic Cells; Evaluation; Gluten; Human; Immunotherapy; In Vitro; Interleukin-15; Macrophage; Patients; Peptides; Reproducibility; Rye cereal; Small Intestines; Testing; Wheat; adaptive immune response; design; screening

Celiac disease (CD) is a human chronic autoimmune disorder of the small intestine driven by adaptive immune responses to gluten peptides in wheat, barley, and rye. The contractor is targeting dendritic cells and macrophages to discovery new tolerogenic adjuvants which when paired with gluten antigens, may enable the first clinically viable immunotherapy for CD patients.

乳糜泻（CD）是一种由对小麦、大麦和黑麦中的谷蛋白肽的适应性免疫应答驱动的人类小肠慢性自身免疫性疾病。承包商正在瞄准树突状细胞和巨噬细胞，以发现新的致耐受性佐剂，当与麸质抗原配对时，可能使CD患者的第一个临床可行的免疫疗法成为可能。